Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Attention Turns To Celgene's Other Pipeline Prospects Following Second Positive Luspatercept Read-Out

Executive Summary

Celgene and Acceleron's novel erythroid maturation agent, luspatercept, has reported positive Phase III results in a second potential indication, beta-thalassemia, and approval filings are confirmed for the first half of 2019.

Advertisement

Related Content

Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?
Celgene Focuses On Deals, Pipeline As Post-Revlimid Future Draws Closer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123386

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel